MapLight Therapeutics Announces $150 Million Private Placement Financing
MapLight Therapeutics secured $150 million in gross proceeds via a private placement, selling 9.2 million shares of common stock at $11.38 per share and issuing pre-funded warrants for an additional 4.0 million shares. Proceeds will primarily fund the advancement of ML-007C-MA, including the ongoing VISTA Phase 2 study in Alzheimer's disease psychosis and the ZEPHYR-2 registrational Phase 3 study in schizophrenia.
Key figures
- Deal Value Usd
- 150000000
- Offering Price
- 11.38
- Cash runway
- through 2028
- Cash position
- $351.3 million
- Prefunded warrants
- 3983168
- Prefunded warrant price
- 11.3799
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.